Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cvs health corp. - CVS

CVS

Close Chg Chg %
76.06 -0.01 -0.01%

Closed Market

76.06

-0.01 (0.01%)

Volume: 2.93M

Last Updated:

Mar 13, 2026, 3:47 PM EDT

Trade Now

Company Overview: cvs health corp. - CVS

CVS Key Data

Open

$76.88

 Day Range

76.04 - 77.17

52 Week Range

58.50 - 85.15

 Market Cap

$96.78B

Shares Outstanding

1.27B

 Public Float

1.27B

Beta

0.49

 Rev. Per Employee

N/A

P/E Ratio

54.69

 EPS

$1.40

Yield

349.68%

 Dividend

$0.67

EX-DIVIDEND DATE

Jan 22, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.75M

  

CVS Performance

1 Week
 
 -2.37%
 
1 Month
 
 -3.07%
 
3 Months
 
 -4.22%
 
1 Year
 
 15.82%
 
5 Years
 
 2.91%
 

CVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About cvs health corp. - CVS

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS At a Glance

CVS Health Corp.
1 CVS Drive
Woonsocket, Rhode Island 02895
Phone 1-401-765-1500 Revenue 402.11B
Industry Drugstore Chains Net Income 1.77B
Sector Retail Trade 2025 Sales Growth 7.894%
Fiscal Year-end 12 / 2026 Employees 300,000
View SEC Filings

CVS Valuation

P/E Current 54.687
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 57.052
Price to Sales Ratio 0.251
Price to Book Ratio 1.341
Price to Cash Flow Ratio 9.48
Enterprise Value to EBITDA 9.976
Enterprise Value to Sales 0.424
Total Debt to Enterprise Value 0.469

CVS Efficiency

Revenue/Employee 1,340,370.00
Income Per Employee 5,893.333
Receivables Turnover 10.109
Total Asset Turnover 1.541

CVS Liquidity

Current Ratio 0.842
Quick Ratio 0.625
Cash Ratio 0.12

CVS Profitability

Gross Margin 13.779
Operating Margin 3.10
Pretax Margin 0.531
Net Margin 0.44
Return on Assets 0.678
Return on Equity 2.345
Return on Total Capital 1.139
Return on Invested Capital 1.177

CVS Capital Structure

Total Debt to Total Equity 106.297
Total Debt to Total Capital 51.526
Total Debt to Total Assets 30.625
Long-Term Debt to Equity 98.579
Long-Term Debt to Total Capital 47.785
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cvs Health Corp. - CVS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
322.79B 358.27B 372.69B 402.11B
Sales Growth
+10.57% +10.99% +4.02% +7.89%
Cost of Goods Sold (COGS) incl D&A
268.17B 303.35B 321.41B 346.70B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.25B 4.37B 4.60B 4.61B
Depreciation
2.44B 2.46B 2.57B 2.63B
Amortization of Intangibles
1.81B 1.91B 2.02B 1.98B
COGS Growth
+11.71% +13.12% +5.95% +7.87%
Gross Income
54.61B 54.93B 51.28B 55.41B
Gross Income Growth
+5.29% +0.57% -6.63% +8.04%
Gross Profit Margin
+16.92% +15.33% +13.76% +13.78%
2022 2023 2024 2025 5-year trend
SG&A Expense
38.21B 39.34B 41.36B 42.94B
Research & Development
- - - -
-
Other SG&A
38.21B 39.34B 41.36B 42.94B
SGA Growth
+3.46% +2.97% +5.13% +3.81%
Other Operating Expense
- - - -
-
Unusual Expense
5.80B 994.00M 1.03B 7.47B
EBIT after Unusual Expense
10.60B 14.59B 8.89B 4.99B
Non Operating Income/Expense
(2.70B) (777.00M) 196.00M 240.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.27B 2.64B 2.94B 3.10B
Interest Expense Growth
-7.98% +16.15% +11.33% +5.38%
Gross Interest Expense
2.27B 2.64B 2.94B 3.10B
Interest Capitalized
- - - -
-
Pretax Income
5.63B 11.17B 6.15B 2.14B
Pretax Income Growth
-45.99% +98.53% -44.97% -65.26%
Pretax Margin
+1.74% +3.12% +1.65% +0.53%
Income Tax
1.46B 2.81B 1.56B 408.00M
Income Tax - Current - Domestic
3.54B 3.48B 2.13B 192.00M
Income Tax - Current - Foreign
- - - 114.00M
-
Income Tax - Deferred - Domestic
(2.08B) (676.00M) (572.00M) 102.00M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.17B 8.37B 4.59B 1.73B
Minority Interest Expense
16.00M 24.00M (28.00M) (40.00M)
Net Income
4.15B 8.34B 4.61B 1.77B
Net Income Growth
-47.55% +101.11% -44.70% -61.68%
Net Margin Growth
+1.29% +2.33% +1.24% +0.44%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
4.15B 8.34B 4.61B 1.77B
Preferred Dividends
- - - -
-
Net Income Available to Common
4.15B 8.34B 4.61B 1.77B
EPS (Basic)
3.1624 6.4934 3.6648 1.3954
EPS (Basic) Growth
-47.27% +105.33% -43.56% -61.92%
Basic Shares Outstanding
1.31B 1.28B 1.26B 1.27B
EPS (Diluted)
3.136 6.4682 3.6561 1.391
EPS (Diluted) Growth
-47.31% +106.26% -43.48% -61.95%
Diluted Shares Outstanding
1.32B 1.29B 1.26B 1.27B
EBITDA
20.65B 19.95B 14.52B 17.07B
EBITDA Growth
+6.16% -3.39% -27.22% +17.60%
EBITDA Margin
+6.40% +5.57% +3.90% +4.25%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 95.043
Number of Ratings 30 Current Quarters Estimate 2.226
FY Report Date 03 / 2026 Current Year's Estimate 7.168
Last Quarter’s Earnings 1.09 Median PE on CY Estimate N/A
Year Ago Earnings 6.75 Next Fiscal Year Estimate 8.179
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 23 23 26 25
Mean Estimate 2.23 1.82 7.17 8.18
High Estimates 2.38 1.98 7.40 8.80
Low Estimate 2.10 1.66 6.97 7.71
Coefficient of Variance 3.57 4.94 1.34 2.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 19
OVERWEIGHT 6 5 5
HOLD 6 7 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cvs Health Corp. - CVS

Date Name Shares Transaction Value
Jan 7, 2026 Prem S. Shah EVP and Group President 61,509 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.13 per share 4,928,716.17
May 20, 2025 Fernando G. Aguirre Director 39,150 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $60.47 per share 2,367,400.50
May 20, 2025 Jeffrey R. Balser Director 11,884 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $60.47 per share 718,625.48
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 41,569 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 2,825,860.62
Apr 4, 2025 Prem S. Shah EVP and Group President 112,289 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 James D. Clark SVP, Cont & Chief Acct Officer 24,707 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 1,679,581.86
Apr 4, 2025 James D. Clark SVP, Cont & Chief Acct Officer 11,240 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 764,095.20
Apr 4, 2025 J. David Joyner President and CEO; Director 51,940 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 3,530,881.20
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 68,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 41,109 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 2,794,589.82
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 50,188 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 3,411,780.24
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 68,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 J. David Joyner President and CEO; Director 226,138 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 21,700 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 1,475,166.00
Apr 4, 2025 Heidi B. Capozzi EVP and Chief People Officer 49,906 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Heidi B. Capozzi EVP and Chief People Officer 95,310 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 6,479,173.80
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 87,336 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 116,257 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 7,903,150.86
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 43,503 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 2,957,333.94
Apr 4, 2025 Steven H. Nelson EVP and President, Aetna 90,455 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cvs Health Corp. in the News

Why neighborhood pharmacies are closing

Retail pharmacies will never be obsolete, according to an analyst. But the industry needs to take a hard look at how many stores are needed and what items they should sell.

CVS Health to cut 2,900 jobs

CVS Health is slashing its headcount by 2,900, or 1% of its total workforce. The layoffs will largely focus on corporate positions, a spokesperson said.